Track topics on Twitter Track topics that are important to you
Nathan A. Pennell, MD, PhD, discusses the actionability of advanced ALK-positive and ROS1-positive non–small cell lung cancer and the drugs that have emerged in the frontline and second-line settings.
Original Article: Leveraging the Growing Arsenal of ALK and ROS1 Inhibitors in NSCLCNEXT ARTICLE
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...